Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human recombinant DNase in cystic fibrosis.

Literature DB >> 7776324

Human recombinant DNase in cystic fibrosis.

A H Thomson¹.

Abstract

Entities: Disease Species

Mesh：

Substances：

Year: 1995 PMID： 7776324 PMCID： PMC1295055

Source DB: PubMed Journal: J R Soc Med ISSN： 0141-0768 Impact factor: 5.344

× No keyword cloud information.

13 in total

1. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis.

Authors: W S CHERNICK; G J BARBERO
Journal: Pediatrics Date: 1959-11 Impact factor: 7.124

2. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

Authors: R C Hubbard; N G McElvaney; P Birrer; S Shak; W W Robinson; C Jolley; M Wu; M S Chernick; R G Crystal
Journal: N Engl J Med Date: 1992-03-19 Impact factor: 91.245

3. Variability of pulmonary function tests in cystic fibrosis.

Authors: P J Cooper; C F Robertson; I L Hudson; P D Phelan
Journal: Pediatr Pulmonol Date: 1990

4. Bronchospasm after inhalation of pancreatic dornase.

Authors: P Raskin
Journal: Am Rev Respir Dis Date: 1968-10

5. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis.

Authors: J Lieberman
Journal: JAMA Date: 1968-07-29 Impact factor: 56.272

6. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

Authors: S Shak; D J Capon; R Hellmiss; S A Marsters; C L Baker
Journal: Proc Natl Acad Sci U S A Date: 1990-12 Impact factor: 11.205

7. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis.

Authors: B G Nickerson; R J Lemen; C B Gerdes; M J Wegmann; G Robertson
Journal: Am Rev Respir Dis Date: 1980-12

8. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

Authors: C Ranasinha; B Assoufi; S Shak; D Christiansen; H Fuchs; D Empey; D Geddes; M Hodson
Journal: Lancet Date: 1993-07-24 Impact factor: 79.321

9. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors: H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal: N Engl J Med Date: 1994-09-08 Impact factor: 91.245

10. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients.

Authors: M Robson; J Abbott; K Webb; M Dodd; J Walsworth-Bell
Journal: Thorax Date: 1992-09 Impact factor: 9.139

10 in total

1. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

Authors: C M Costello; C M O'Connor; G A Finlay; P Shiels; M X FitzGerald; J P Hayes
Journal: Thorax Date: 1996-06 Impact factor: 9.139

2. Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

Authors: Mike Wilton; Megan J Q Wong; Le Tang; Xiaoye Liang; Richard Moore; Michael D Parkins; Shawn Lewenza; Tao G Dong
Journal: Infect Immun Date: 2016-07-21 Impact factor: 3.441

Human recombinant DNase in cystic fibrosis.

1. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis.

2. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

3. Variability of pulmonary function tests in cystic fibrosis.

4. Bronchospasm after inhalation of pancreatic dornase.

5. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis.

6. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

7. Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis.

8. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis.

9. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

10. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients.

1. Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis.

2. Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

3. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

Review 4. Liver transplantation for hepatic cirrhosis in cystic fibrosis.

Review 5. Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system.

Review 6. NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology.

7. PAD4-dependent NETs generation are indispensable for intestinal clearance of Citrobacter rodentium.

8. Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress.

9. Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes.

Review 10. Bacterial Biofilm Control by Perturbation of Bacterial Signaling Processes.